Nivolumab for malignant transformation of ovarian mature cystic teratoma

Mature cystic teratoma of the ovary (MCT) occasionally undergoes malignant transformation (MT) that is resistant to chemotherapy and has a poor prognosis. We experienced a case of clinically aggressive MCT-MT that invades surrounding organs and tissues. Although tumor was resected entirely, a rapid...

Descripción completa

Detalles Bibliográficos
Autores principales: Yoshimura, Kayoko, Yamanoi, Koji, Kanai, Masashi, Okunomiya, Asuka, Sagae, Yusuke, Sunada, Masumi, Taki, Mana, Ukita, Masayo, Chigusa, Yoshitsugu, Horie, Akihito, Yamaguchi, Ken, Hamanishi, Junzo, Minamiguchi, Sachiko, Yamamoto, Noboru, Muto, Manabu, Mandai, Masaki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9764164/
https://www.ncbi.nlm.nih.gov/pubmed/36560959
http://dx.doi.org/10.1016/j.gore.2022.101115
Descripción
Sumario:Mature cystic teratoma of the ovary (MCT) occasionally undergoes malignant transformation (MT) that is resistant to chemotherapy and has a poor prognosis. We experienced a case of clinically aggressive MCT-MT that invades surrounding organs and tissues. Although tumor was resected entirely, a rapid tumor recurrence occurred during postoperative chemotherapy (paclitaxel + ifosfamide + cisplatin). The results of comprehensive genomic profiling test performed early in the postoperative period showed a high tumor mutational burden of 23 mutations/Mb. Treatment with nivolumab monotherapy has promptly been initiated and has been very successful for more than one year.

Ejemplares similares